Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast09
2020-004074-21Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of trastuzumab deruxtecan, pertuzumab, trastuzumab, docetaxel and paclitaxel in HER2-positive breast cancer (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival by blinded independent central review. Started Feb 2021; status: active.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on 2020-004074-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004074-21.